| Purpose | (Clinical Focus: This value set focuses on medications used in transgender women for feminization and fertility suppression. It captures specific GnRH agonist medications and their dosages commonly included in transfeminine hormone replacement therapy (HRT).),(Data Element Scope: This value set defines a specific category of medications within the broader context of gender-affirming hormone therapy. It focuses on GnRH agonists, which work by suppressing the production of sex hormones (estradiol and testosterone). This suppression can be a desired outcome in transfeminine HRT, particularly in combination with estrogen therapy.),(Inclusion Criteria: Leuprolide acetate: This medication is included in various injectable formulations with a wide range of dosages (3.75mg/ml, 5mg/ml, 7.5mg/ml, 11.25mg/ml, 15mg/ml, 20mg/ml, 30mg/ml, 60mg/ml, 120mg/ml). Prefilled syringes and injection solutions are included.
Goserelin: This medication is included as a drug implant in two dosage options (3.6mg and 10.8mg).
Similar to other value sets for transfeminine HRT medications, the specific GnRH agonist dosage and formulation prescribed will be individualized by a healthcare professional based on the patient's needs and treatment plan.),(Exclusion Criteria: This value set excludes other medications used in transfeminine HRT, such as estrogens, antiandrogens, and progestins.
It does not capture information about the frequency of administration (e.g., monthly, quarterly) beyond what is included in the concept codes (e.g., some medications mention multi-month supplies).
It excludes any medications not classified as GnRH agonists.) |
FHIR